UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

Revista española de enfermedades digestivas, 2016-02, Vol.108 (2), p.104-105

2016

Volltextzugriff (PDF)

Bayes‐based dosing of infliximab in inflammatory bowel diseases: Short‐term efficacy

British journal of clinical pharmacology, 2021-02, Vol.87 (2), p.494-505

2021

Volltextzugriff (PDF)

Disease-modifying treatments for patients with multiple sclerosis in Spain

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2023-07, Vol.47 (4), p.155

2023

Volltextzugriff (PDF)

Relationship between vedolizumab serum concentrations in the induction phase and early and sustained response in the first year of treatment in patients with ulcerative colitis

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2021-12, Vol.45 (7), p.38

2021

Volltextzugriff (PDF)

85 - MONITORIZACIÓN PROACTIVA DE NIVELES TERAPÉUTICOS DE INFLIXIMAB DURANTE LA FASE DE INDUCCIÓN EN ENFERMEDAD INFLAMATORIA INTESTINAL

Gastroenterología y hepatología, 2023-03, Vol.46, p.S117-S117

2023

Volltextzugriff (PDF)

Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design

Therapeutic drug monitoring, 2020-02, Vol.42 (1), p.102

2020

Volltextzugriff (PDF)

Is there a difficulty in maintaining haemoglobin target levels in pre-dialysis patients treated with erythropoiesis-stimulating agents?

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2014, Vol.34 (2), p.263

2014

Volltextzugriff (PDF)

Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial

Frontiers in medicine, 2021-06, Vol.8, p.691712-691712

2021

Volltextzugriff (PDF)

SAT-009-Pharmacokinetics of ertapenem in plasma and ascitic fluid in cirrhotic patients with spontaneous bacterial peritonitis

Journal of hepatology, 2019-04, Vol.70 (1), p.e628-e629

2019

Volltextzugriff (PDF)

HLA-B57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience

Pharmacogenetics and genomics, 2016-08, Vol.26 (8), p.390-396

2016

Volltextzugriff (PDF)

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Therapeutic drug monitoring, 2024-06, Vol.46 (3), p.291

2024

Volltextzugriff (PDF)

Social pharmacology of the information about prescription drugs on the Internet

Medicina clínica, 2007-10, Vol.129 (14), p.558-9; author reply 559

2007

Volltextzugriff (PDF)

[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain

Farmacia hospitalaria, 2023-07, Vol.47 (4), p.T155-T160

2023

Volltextzugriff (PDF)

Estudio observacional retrospectivo de la utilización de omalizumab en el tratamiento del asma grave persistente

Farmacia Hospitalaria, 2013-10, Vol.37 (5), p.399-405

2013

Volltextzugriff (PDF)

Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2012, Vol.32 (2), p.221

2012

Volltextzugriff (PDF)

Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy

The Annals of pharmacotherapy, 2008-05, Vol.42 (5), p.640

2008

Volltextzugriff (PDF)

Tratamientos modificadores de la enfermedad en pacientes con esclerosis múltiple en España

Farmacia hospitalaria, 2023-07, Vol.47 (4), p.155-160

2023

Volltextzugriff (PDF)

Farmacología social de la información sobre medicamentos de prescripción en internet

Medicina clínica, 2007-10, Vol.129 (14), p.558-559

2007

Volltextzugriff (PDF)

Pharmacokinetics of α1-Antitrypsin Replacement Therapy in Severe Congenital Emphysema

Archivos de bronconeumología (English ed.), 2006-10, Vol.42 (10), p.553-556

2006

Volltextzugriff (PDF)

Pharmacokinetics of α 1-Antitrypsin Replacement Therapy in Severe Congenital Emphysema

Archivos de bronconeumología (English ed.), 2006, Vol.42 (10), p.553-556

2006

Volltextzugriff (PDF)

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

Revista española de enfermedades digestivas, 2016-02, Vol.108 (2), p.104-105

2016

Volltextzugriff (PDF)

Dosage adjustment for hepatic dysfunction

Revista española de enfermedades digestivas, 2013-06, Vol.105 (5), p.305-306

2013

Volltextzugriff (PDF)

Dosage adjustment for hepatic dysfunction

Revista española de enfermedades digestivas, 2013-05, Vol.105 (5), p.305-306

2013

Volltextzugriff (PDF)

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

Revista española de enfermedades digestivas, 2015

2015

Volltextzugriff (PDF)

[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2023-07, Vol.47 (4), p.T155

2023

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Aktive Filter

ThemaNeurosciences & Neurology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(68)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(30)
Science & Technology
(30)
Life Sciences & Biomedicine
(27)
Female
(19)
Pharmacology & Pharmacy
(19)
Male
(18)
Adult
(11)
Middle Aged
(11)
Aged
(9)
Infectious Diseases
(8)
Pharmacokinetics
(6)
Spain
(6)
Metabolism
(5)
Patients
(5)
Social Sciences
(5)
Therapeutic Drug Monitoring
(5)
Biological And Medical Sciences
(4)
Brain Mapping
(4)
Functional Magnetic Resonance Imaging
(4)
Geriatrics & Gerontology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

Bayes‐based dosing of infliximab in inflammatory bowel diseases: Short‐term efficacy

Disease-modifying treatments for patients with multiple sclerosis in Spain

Relationship between vedolizumab serum concentrations in the induction phase and early and sustained response in the first year of treatment in patients with ulcerative colitis

85 - MONITORIZACIÓN PROACTIVA DE NIVELES TERAPÉUTICOS DE INFLIXIMAB DURANTE LA FASE DE INDUCCIÓN EN ENFERMEDAD INFLAMATORIA INTESTINAL

Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design

Is there a difficulty in maintaining haemoglobin target levels in pre-dialysis patients treated with erythropoiesis-stimulating agents?

Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial

SAT-009-Pharmacokinetics of ertapenem in plasma and ascitic fluid in cirrhotic patients with spontaneous bacterial peritonitis

HLA-B57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Social pharmacology of the information about prescription drugs on the Internet

[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain

Estudio observacional retrospectivo de la utilización de omalizumab en el tratamiento del asma grave persistente

Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease

Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy

Tratamientos modificadores de la enfermedad en pacientes con esclerosis múltiple en España

Farmacología social de la información sobre medicamentos de prescripción en internet

Pharmacokinetics of α1-Antitrypsin Replacement Therapy in Severe Congenital Emphysema

Pharmacokinetics of α 1-Antitrypsin Replacement Therapy in Severe Congenital Emphysema

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

Dosage adjustment for hepatic dysfunction

Dosage adjustment for hepatic dysfunction

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain

Aktive Filter

Suchergebnisse filtern